SEC For	m 4 FORM	4 U	NITE	D STAT	FES :	SEC	UR	ITIE	SAN	JD F	XCHAN	IGE	сом	MISS	5101	N			
			ES SECURITIES AND EXCHANGE CON Washington, D.C. 20549										OMB APPROVA						
to Section 16. Form 4 or Form 5 obligations may continue. See						Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estim			MB Number: 3235-0287 stimated average burden burs per response: 0.5		en
1. Name and Address of Reporting Person* Parini Michael					VE	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)				wner	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 02/10/2021								EVP, Chief Adm, Leg & BD Off					
50 NORTHERN AVENUE (Street) BOSTON MA 02210					4. lf /	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)						tive Securities Acquired, Disposed of, or Benefi									Perso				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)				tion	on 2A. Deemed Execution Date,			3.4. SecuritieTransaction Code (Instr. 8)5)			s Acquir	r 5 und S E	5. Amount of Securities Beneficially Owned Following		Form (D) c	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	т	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 02/10/2					2021)21			F		2,563	D	\$21	4.16	.16 54,664			D	
		Tal	ble II -								osed of, o convertib				wnec	ł			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/N		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)				9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Direct or Indi (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownershi (Instr. 4)
					Code		(A)	(D)	Date	sable	Expiration Date		Amount or Number of Shares						

Explanation of Responses:

Remarks:

/s/ Sabrina Yohai, Attorney-in-02/12/2021

<u>Fact</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.